Christopher M. Yea's most recent trade in KalVista Pharmaceuticals Inc was a trade of 60,000 Common Stock done . Disclosure was reported to the exchange on July 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2025 | 60,000 | 158,189 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 15.69 per share. | 08 Jul 2025 | 30,250 | 127,939 (0%) | 0% | 15.7 | 474,698 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 3,125 | 37,500 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 3,125 | 100,115 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 11.31 per share. | 22 May 2025 | 1,926 | 98,189 (0%) | 0% | 11.3 | 21,782 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 3,750 | 99,307 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 3,750 | 56,250 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 21 May 2025 | 2,317 | 96,990 (0%) | 0% | 11.9 | 27,516 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 4,205 | 98,157 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 11.84 per share. | 17 May 2025 | 2,600 | 95,557 (0%) | 0% | 11.8 | 30,791 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 2,431 | 4,861 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 1,774 | 7,095 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 3,125 | 40,625 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 3,125 | 95,870 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 21 Feb 2025 | 1,918 | 93,952 (0%) | 0% | 10.0 | 19,218 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 4,204 | 95,346 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 9.82 per share. | 17 Feb 2025 | 2,601 | 92,745 (0%) | 0% | 9.8 | 25,553 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 2,430 | 7,292 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 1,774 | 8,869 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | M. Christopher Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 3,125 | 43,750 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Yea Christopher M. | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 3,125 | 93,105 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Yea M. Christopher | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 9.87 per share. | 22 Nov 2024 | 1,963 | 91,142 (0%) | 0% | 9.9 | 19,378 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 11,496 | 97,172 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 7,291 | 0 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 9.26 per share. | 17 Nov 2024 | 7,192 | 89,980 (0%) | 0% | 9.3 | 66,573 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 2,431 | 9,722 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 1,774 | 10,643 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2024 | 3,125 | 87,592 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2024 | 3,125 | 46,875 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 12.40 per share. | 22 Aug 2024 | 1,916 | 85,676 (0%) | 0% | 12.4 | 23,758 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 11,495 | 91,569 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 7,292 | 7,291 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 17 Aug 2024 | 7,102 | 84,467 (0%) | 0% | 12.0 | 85,318 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 2,430 | 12,153 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 1,773 | 12,417 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 18,789 | 91,684 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 11.76 per share. | 17 May 2024 | 11,610 | 80,074 (0%) | 0% | 11.8 | 136,586 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 7,292 | 14,583 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 7,292 | 0 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,431 | 14,583 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 1,774 | 14,190 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | M. Christopher Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 18,788 | 84,948 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Yea Christopher M. | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 14.11 per share. | 17 Feb 2024 | 12,053 | 72,895 (0%) | 0% | 14.1 | 170,124 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher Yea M. | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 7,292 | 7,292 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher Yea M. | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 7,292 | 29,167 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Yea Christopher M. | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 2,430 | 17,014 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | M. Christopher Yea | CHIEF DEVELOPMENT OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 1,774 | 15,964 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 14 Feb 2024 | 39,886 | 66,160 (0%) | 0% | 15.0 | 598,661 | Common Stock |
| KalVista Pharmaceuticals Inc | M. Yea Christopher | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 60,000 | 106,046 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | M. Yea Christopher | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 29,167 | 29,167 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 11,494 | 48,804 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 7,291 | 0 | - | - | Performance Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 10.73 per share. | 17 Aug 2023 | 7,142 | 41,662 (0%) | 0% | 10.7 | 76,624 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 2,430 | 21,875 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 1,773 | 19,512 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 2,430 | 26,736 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2022 | 1,774 | 35,371 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2022 | 1,774 | 24,833 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 5.44 per share. | 21 Nov 2022 | 1,139 | 34,232 (0%) | 0% | 5.4 | 6,196 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 1,773 | 34,742 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 1,773 | 26,607 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 14.96 per share. | 17 Aug 2022 | 1,145 | 33,597 (0%) | 0% | 15.0 | 17,130 | Common Stock |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 28,380 | 28,380 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Christopher M. Yea | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 18,920 | 18,920 | - | - | Employee Stock Option (Right to Buy) |